J&J invests in experimental drugs as competitive threats loom
New York
JOHNSON & JOHNSON is investing in a collection of experimental drugs with blockbuster potential, treating widespread illnesses such as blood cancer and Alzheimer's disease, to help rise above looming competitive threats to its pharmaceutical business.
The world's biggest maker of health products said on Wednesday it plans to seek regulatory approval for more than 10 new drugs by 2019 with potential annual sales of more than US$1 billion apiece. That would help J&J regain some momentum in what has become its biggest division, whose drugs approved in the last few years are projected to lag behind its biggest rivals.
TRENDING NOW
High Court rules against Julius Baer’s Singapore trust arm in US$50 million family trust dispute
MSCI proposes standalone status for Indonesia; Jakarta stocks plunge 8%
Once staunchly pro-China, Malaysian Chinese businesses are now distancing themselves from Beijing
No chicken feed: How Malayan Flour Mills built an empire from flour to fowl
